Investments in longevity have seen a significant increase from $525 million in 2013 to $9.26 billion in 2021, as reported by Longevity.Technology. Longevity research has advanced, leading to a better comprehension of aging and the potential interventions to promote healthy living. The awareness among the public and the rapid progress in longevity research indicate a conducive environment for impactful investments in anti-aging and longevity-related ventures.
At LongeVC, we are optimistic about the future of our field. Our founding partner Sergey Jakimov shared his views on this topic in the recent article by Neal Templin, published in Barron's. In his commentary, Sergey mentions some of our portfolio companies, Turn Biotechnologies and PreComb.
Read the full article here.
At LongeVC, we are optimistic about the future of our field. Our founding partner Sergey Jakimov shared his views on this topic in the recent article by Neal Templin, published in Barron's. In his commentary, Sergey mentions some of our portfolio companies, Turn Biotechnologies and PreComb.
Read the full article here.